Viewing nowCombinationHugliam XR 50/1000 mg (Sitagliptin, Metformin)
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.

MFDS item code 202300603 · Approved 2023.02.17 · Insurance code 670609060
Improvement of glycemic control in patients with type 2 diabetes
This medication contains sitagliptin and metformin to help patients with type 2 diabetes to regulate their blood sugar more effectively while managing their diet and exercising.
In antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. Take 1 tablet of this medicine 100/1000 mg extended-release tablets once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no previous experience of pharmacological treatment for diabetes whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin treatment: For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient’s current metformin dose. Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. Patients currently taking immediate-release tablets at a dose of 850 mg or 1000 mg twice daily as their metformin dose may start with 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.
This medication includes sitagliptin and metformin, which are used in diabetes treatment. The sitagliptin component can rarely cause serious allergic reactions, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur within three months of starting treatment, the medication should be stopped immediately and a doctor should be consulted. Also, there is a risk of acute pancreatitis, inflammation of the pancreas, so if symptoms such as abdominal pain, nausea, vomiting, or fever appear, you should inform healthcare personnel quickly. The metformin component should not be used in patients with poor kidney function, severe infection or dehydration, or acute cardiac disease, as there is a risk of lactic acidosis, a serious metabolic disorder, especially in cases of decreased kidney function. Lactic acidosis can manifest with symptoms such as muscle pain, fatigue, difficulty breathing, abdominal pain, and reduced consciousness; if such symptoms occur, medical attention should be sought immediately. Patients should have their kidney function checked regularly before and during treatment with this medication, and if kidney function declines, the medication should be discontinued. Furthermore, this medication should not be used in pregnant or potentially pregnant women, breastfeeding women, or children under 18 years of age. During treatment with this medication, excessive alcohol consumption should be avoided, and it may be necessary to stop taking the medication for a certain period before and after surgery. There is a risk of hypoglycemia, so care should be taken to avoid skipping meals or eating irregularly, and during intense exercise; if taken with other blood sugar-lowering medications, symptoms of hypoglycemia may appear, so patients should inform healthcare personnel immediately if symptoms occur. Some patients may experience side effects such as diarrhea, nausea, headache, upper respiratory infection, and if symptoms are severe or persistent, a doctor should be consulted. Lastly, if blisters appear on the skin or severe joint pain occurs while taking this medication, it should be stopped immediately, and medical advice should be sought.
anaphylaxis
Not everyone experiences these, and they can vary from person to person.
This medication should be kept in a tightly sealed container to avoid exposure to air or moisture. It should also be stored at room temperature between 1 and 30 degrees Celsius, avoiding excessively hot or cold places.
Bright green oval extended-release film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.